The reason why the CD47-SIRPα pathway deserves attention in GBM patients is because the majority of immune cells within brain tumors are macrophages91, which often compose up to 30%–50% of the tumor mass and include tissue-resident microglia and bone marrow-derived monocytes and macrophages (BMDMs)56,92. The gene discussed is SIRPA; the disease is glioblastoma.